NICOX (EPA:COX) | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Home
Companies
NICOX

PRESS RELEASE

published on 08/08/2025 at 07:30, 3 months 27 days ago

Nicox Extends Existing Flexible Equity Financing
Nicox extends PACEO equity line with Vester Finance by adding 5 million shares. NCX 470 Denali Phase 3 results expected in mid-August to mid-September 2025

Equity Financing Nicox Phase 3 Results NCX 470 Denali Vester Finance
BRIEF

published on 06/30/2025 at 07:35, 5 months 4 days ago

Nicox Achieves Milestone in NCX 470 Phase 3 Clinical Trial

Glaucoma Ocular Hypertension Phase 3 Trial Nicox NCX 470
PRESS RELEASE

published on 06/30/2025 at 07:30, 5 months 4 days ago

Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial
Nicox announces completion of Denali Phase 3 trial for NCX 470 eye drop, expecting results mid-August to mid-September 2025. NDA submission in the U.S. targeted for H1 2026

Phase 3 Trial Ophthalmology Nicox NCX 470 NDA Submission
BRIEF

published on 06/06/2025 at 07:35, 5 months 28 days ago

Nicox Announces Shareholders’ Meeting and Ad Hoc Representative

Voting Rights Shareholders’ Meeting Euronext Growth Nicox Ad Hoc Representative
PRESS RELEASE

published on 06/06/2025 at 07:30, 5 months 28 days ago

Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 27, 2025 and appointment of an ad hoc representative
Nicox SA announces Ordinary and Extraordinary Shareholders' Meeting on June 27, 2025, appoints ad hoc representative. Details on agenda, proxy voting, and meeting participation

Shareholders' Meeting Proxy Voting Nicox SA Ad Hoc Representative Meeting Participation
BRIEF

published on 05/27/2025 at 07:35, 6 months 8 days ago

Nicox secures up to €3 million from Kowa to advance NCX 470

Ocular Hypertension Phase 3 Nicox NCX 470 Kowa
BRIEF

published on 05/14/2025 at 07:35, 6 months 21 days ago

Nicox Reports Findings from Whistler Phase 3b Glaucoma Trial

Glaucoma Nicox NCX 470 Whistler Phase 3b Intraocular Pressure
PRESS RELEASE

published on 05/14/2025 at 07:30, 6 months 21 days ago

Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial
Nicox announces positive results of Whistler Phase 3b glaucoma trial with NCX 470 showing efficacy in lowering intraocular pressure via dual mechanism action of nitric oxide and prostaglandin analogs. Safety profile consistent with previous trial

Nicox NCX 470 Glaucoma Trial Whistler Phase 3b Intraocular Pressure
BRIEF

published on 04/30/2025 at 07:35, 7 months 4 days ago

Nicox Reports Full Year 2024 Financials

Net Loss Cash Reserves Nicox Financial Results VYZULTA Revenue Sale NCX 470 Trials
PRESS RELEASE

published on 04/30/2025 at 07:30, 7 months 4 days ago

Nicox Provides Full Year 2024 Financial Results
Nicox reports €7.9 million revenue for 2024 with exceptional income of €13.7 million from VYZULTA transfer. Cash of €10.5 million and NCX 470 Phase 3 trial results expected in Q3 2025

Financial Results Revenue Nicox NCX 470 VYZULTA

Accesswire

Published on 12/05/2025 at 02:35, 3 hours 50 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 3 hours 55 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 5 hours 25 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 20 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 25 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 2 hours 54 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 34 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 9 hours 59 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 10 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 14 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 12 hours 25 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 40 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 40 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 24 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE